Halozyme Therapeutics

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$354,264
$325,719
$264,861
$298,008
Gross Profit
299,022
279,360
216,458
255,953
EBITDA
284,625
229,834
168,802
203,169
EBIT
223,254
209,332
148,353
182,754
Net Income
175,225
165,160
118,095
137,012
Net Change In Cash
354,264
325,719
264,861
298,008
Free Cash Flow
175,567
98,148
153,271
175,415
Cash
419,665
61,861
176,328
115,850
Basic Shares
122,331
124,158
126,644
129,424

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$1,015,324
$829,253
$660,116
$443,310
Gross Profit
855,907
636,892
520,812
361,897
EBITDA
656,539
451,947
315,506
278,899
EBIT
575,227
367,091
265,865
275,902
Net Income
444,091
281,594
202,129
402,710
Net Change In Cash
1,015,324
829,253
660,116
443,310
Cost of Revenue
115,476
-28,984
Free Cash Flow
468,368
373,277
235,300
297,983
Cash
115,850
118,370
234,195
118,719
Basic Shares
129,424
134,197
140,608
146,796

Earnings Calls

QuarterEPS
2025-09-30
$1.72
2025-06-30
$1.54
2025-03-31
$1.11
2024-12-31
$1.26